News Feature

Filter By:

Article Type
  • With the first wave of cancer immunotherapies continuing to show their potential to revolutionize treatment paradigms, major pharmaceutical companies are leaving no stone unturned in the search for winning combination therapies that harness immuno-oncology drugs.

    • Chris Morrison
    News Feature
  • A commercial environment reinvigorated by improved fundamentals—increased regulatory flexibility and the emergence of exciting new scientific opportunities and innovative business models—has set the stage for a resurgence in the antibiotics space that has already led to an uptick in early-stage venture investment and strategic partnerships.

    • Suzanne Elvidge
    News Feature
  • With the help of BioCentury, Biopharma Dealmakers is provides an update on the deal-trends analysis in the antibody field.

    • Biopharma Dealmakers
    News Feature
  • The dermatology space is emerging from an active period of diversification and consolidation that has opened up new partnering opportunities. Besides the cosmetic market, the medical segment has also entered a growth phase propelled by three indications: melanoma, psoriasis and systemic lupus erythematosus.

    • Gaspar Taroncher-Oldenburg
    News Feature
  • Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as bispecifics and antibody-drug conjugates is now opening up new opportunities.

    • Rachel Brazil
    News Feature
  • Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing.

    • Chris Morrison
    News Feature
  • Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.

    • Melanie Brazil
    News Feature
  • Next-generation sequencing platforms are building market share not only in the research setting but also increasingly in population research and clinical applications.

    • Melanie Brazil
    News Feature
  • Venture capital investment in devices remains lackluster, but megamergers and startups in digital health, drug delivery and minimally invasive technology are providing new impetus to today’s evolving medical technology industry.

    • Aaron Bouchie
    News Feature
  • Although specific age-related disorders such as Alzheimer’s disease continue to be a focus of research and development investment and dealmaking activity, companies are also beginning to approach aging in a broader way.

    • Suzanne Elvidge
    News Feature